SEC Form 4 · accession 0001140361-18-033743
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John T. Maxwell
Officer — SVP-Chief Financial Officer
Period of report
Jul 24, 2018
Accepted (ET)
Jul 26, 2018 · 9:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001398733
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Purchase)F1 | $15.00 | Jul 24, 2018 | A | 36,120 | A | — | Jul 24, 2028 | Common Stock | 36,120 | 36,120 | D |
Explanation of responses
- F1The shares underlying the options vest as follows: 25% of the underlying shares vest on the first anniversary of the grant date, 25% of the underlying shares vest on the second anniversary of the grant date and the remaining 50% of the underlying shares vest on the third anniversary of the grant date, subject in each case to Mr. Maxwell's continuous service with the Issuer from the grant date through the applicable vesting date.